Industry Attention Turning to Cellceutix Corp. (CTIX.OB) as a Result of Cancer and Autism Research
Since Cellceutix began researching and developing Kevetrin for the treatment of multi-drug resistant cancers, the company's management team knew that they were on to something with great potential. At first, Kevetrin started as a compound that was being developed for head and neck cancers, but when it was discovered in pre-clinical trials that it could possibly be an effective chemotherapy treatment for strains of cancer that we non-responsive to standard therapies today, the realm of humanitarian and shareholder benefits greatly increased. The pre-clinical research required to file an Investigational New Drug (IND) application with the FDA has now been concluded…